- Home
- HST vs NBIX Comparison
HST vs NBIX Comparison
Compare HST & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HST
- NBIX
- Stock Information
- Founded
- HST 1927
- NBIX 1992
- Country
- HST United States
- NBIX United States
- Employees
- HST N/A
- NBIX N/A
- Industry
- HST Real Estate Investment Trusts
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HST Real Estate
- NBIX Health Care
- Exchange
- HST Nasdaq
- NBIX Nasdaq
- Market Cap
- HST 11.9B
- NBIX 11.6B
- IPO Year
- HST N/A
- NBIX 1996
- Fundamental
- Price
- HST $16.34
- NBIX $120.69
- Analyst Decision
- HST Buy
- NBIX Buy
- Analyst Count
- HST 12
- NBIX 21
- Target Price
- HST $20.54
- NBIX $168.35
- AVG Volume (30 Days)
- HST 9.6M
- NBIX 1.6M
- Earning Date
- HST 02-19-2025
- NBIX 02-06-2025
- Dividend Yield
- HST 5.51%
- NBIX N/A
- EPS Growth
- HST N/A
- NBIX 33.20
- EPS
- HST 0.99
- NBIX 3.29
- Revenue
- HST $5,691,000,000.00
- NBIX $2,355,300,000.00
- Revenue This Year
- HST N/A
- NBIX $16.29
- Revenue Next Year
- HST $3.48
- NBIX $16.90
- P/E Ratio
- HST $16.51
- NBIX $36.68
- Revenue Growth
- HST 7.03
- NBIX 24.81
- 52 Week Low
- HST $15.71
- NBIX $110.95
- 52 Week High
- HST $21.31
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- HST 40.56
- NBIX 35.76
- Support Level
- HST $16.20
- NBIX $113.00
- Resistance Level
- HST $17.16
- NBIX $118.61
- Average True Range (ATR)
- HST 0.39
- NBIX 4.28
- MACD
- HST 0.05
- NBIX -2.22
- Stochastic Oscillator
- HST 30.51
- NBIX 18.81
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.